Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Bulk Raw Materials Etravirine Powder
Product Overview:
Etravirine (etravirine), chemically known as 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]pyrimidin-4-yl]-oxy]-3,5-dimethylbenzylnitrile, is a new generation of non-nucleoside reverse transcriptase inhibitors (NNRTIs) developed by Tibotec, a subsidiary of Johnson & Johnson and was approved for marketing in January 2008 by the US FDA. It became one of the important components of highly effective antiretroviral therapy (HAART) drugs. NNRTIs have made great contributions to the reduction of AIDS morbidity and mortality in clinical practice.
Bulk Raw Materials Etravirine Powder Attributes
CAS:269055-15-4
MF:C20H15BrN6O
MW:435.28
EINECS:682-331-6
Specification: 99% min Etravirine Powder
Sample: Etravirine Powder
Packaging:1kg/bag, 25kg/drum
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Bulk Raw Materials Etravirine Powder Details
Etravirine Powder Usage and Synthesis.
Etravirine, in combination with other antiretroviral agents, is indicated for the treatment of antiretroviral treatment-experienced adult patients with human immunodeficiency virus type I (HIV-1) infection.
Patients are required to have evidence of viral replication and evidence of resistance to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents.
The indication is based on an analysis of Week 48 results from 2 randomised, double-blind, placebo-controlled Phase III clinical trials.
Both trials were conducted in previously treated patients with resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) (present at screening and/or documented in the medical record) and resistance to protease inhibitors (PIs), with the addition of this product to background therapy (BR).
The following should be considered when using this product: the patient's treatment history as well as resistance testing may guide treatment with this product.
The combination of only this product plus a nucleoside or nucleotide reverse transcriptase inhibitor is not recommended in patients with virological failure following NNRTI therapy.
This product is not recommended for use in children, adolescents, and adult patients receiving initial antiviral therapy.
Uses and functions of Etravirine.
The following should be considered when using Etravirine: the patient's treatment history as well as resistance testing may guide treatment with this product.
The combination of only this product plus a nucleoside or nucleotide reverse transcriptase inhibitor is not recommended in patients who have virological failure following NNRTI therapy. This product is not recommended for use in children, adolescents, and adult patients receiving initial antiviral therapy.
Pharmacological Effects of Etravirine.
Etravirine may be used in combination with other antiretroviral drugs in adult HIV-1-infected patients who have developed drug resistance after initial treatment with antiretroviral drugs.
Etravirine belongs to the group of non-nucleoside reverse transcriptase inhibitors (NNRTIs) of human immunodeficiency virus type 1 (HIV-1), which bind directly to the HIV-1 reverse transcriptase enzyme and block both RNA-dependent and DNA-dependent DNA polymerase activity by disrupting the enzyme's catalytic site.
Etravirine does not inhibit human alpha, beta and gamma DNA polymerases .
Production method of Etravirine Powder.
Etravirine has a high genetic barrier to resistance development. In the phase IIb trial, among multiple-treatment patients, including those infected with NNRTIs-resistant and protease inhibitor (PIs)-resistant viruses, TMC125 was active against existing NNRTIs-resistant HIV and was similarly tolerated to controls.
